U.S. Markets closed

XOMA Corporation (XOMA)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
7.42+0.19 (+2.63%)
At close: 3:59PM EDT
People also watch
CTICVICLIMMUAGENVVUS

XOMA Corporation

2910 Seventh Street
Berkeley, CA 94710
United States
510-204-7200
http://www.xoma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees18

Key Executives

NameTitlePayExercisedAge
Mr. James R. NealChief Exec. Officer and Director507.01kN/A61
Mr. Thomas BurnsChief Financial Officer and Sr. VP of Fin.392.93kN/A43
Mr. Denis J. QuinlanSr. Corp. Counsel and Corp. Sec.N/AN/AN/A
Dr. Kirk W. Johnson Ph.D.VP of Devel.N/AN/A57
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

XOMA Corporation discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. Its preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.

Corporate Governance

XOMA Corporation’s ISS Governance QualityScore as of July 1, 2017 is 3. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 2; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.